title: Preventive effect of a proteasome inhibitor on the formation of accelerated atherosclerosis in rabbits with uremia.
abstract: Inflammation plays a central role in the pathogenesis of atherosclerosis. This study investigated whether the proteasome inhibitor has the same preventive effect on the formation of accelerated atherosclerosis in rabbits with uremia compared with a NF-kappaB inhibitor. New Zealand white rabbits were subjected to five-sixths nephrectomy (chronic renal failure [CRF]) or to a sham operation. Rats in each group were randomly assigned into three subgroups (n = 24 in each group) and treated with repeated intramuscular injections of proteasome inhibitor MG132 or NF-kappaB inhibitor PDTC for a specified period. Compared with sham rabbits, CRF rabbits displayed typical atherosclerotic changes (endothelial cell damage, intimal thickens, and appearance of foam cells). CRF rabbits had significantly higher levels of proteasome activity, NF-kappaB mRNA, protein, and DNA binding activity as well as tumor necrosis factor-a and proliferative cell nuclear antigen protein expression in aortic wall cells. CRF rabbits also showed lower levels of IkappaBalpha. Compared with CRF rabbits, CRF rabbits treatment with proteasome inhibitor MG132 showed restoration of IkappaBalpha mRNA and protein expression and decreased NF-kappaB DNA binding activity and tumor necrosis factor-a expression. Treatment with either proteasome inhibitor MG132 or NF-kappaB inhibitor PDTC could reverse these pathologic changes in the aortic wall cells of CRF rabbits. A comparison between the inhibitory effects of the two treatments revealed no statistical difference. These results suggest that ubiquitin-proteasome activation play a pivotal role in the pathogenesis of uremia-accelerated atherosclerosis. The ubiquitin-proteasome signaling pathway in aortic cells may therefore be an important target for preventing uremia-accelerated atherosclerosis.
authors.affiliation: Institute of Nephrology of Chongqing and Department of Nephrology, Xinqiao Hospital, The Third Military Medical University, Chongqing, PR China. fxb12@yahoo.com.cn
authors.forename: Bing
authors.initials: B
authors.lastname: Feng
authors.forename: Yaoquan
authors.initials: Y
authors.lastname: Zhang
authors.forename: Jiao
authors.initials: J
authors.lastname: Mu
authors.forename: Zilin
authors.initials: Z
authors.lastname: Ye
authors.forename: Wei
authors.initials: W
authors.lastname: Zeng
authors.forename: Wei
authors.initials: W
authors.lastname: Qi
authors.forename: Zhifeng
authors.initials: Z
authors.lastname: Luo
authors.forename: Yanhong
authors.initials: Y
authors.lastname: Guo
authors.forename: Xu
authors.initials: X
authors.lastname: Yang
authors.forename: Fahuan
authors.initials: F
authors.lastname: Yuan
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000150:complications / Q000201:enzymology / Q000517:prevention & control*; D007976:Leupeptins / Q000494:pharmacology / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D061988:Proteasome Inhibitors; D011817:Rabbits; D014511:Uremia / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology
chemical_list: D007976:Leupeptins; D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D046988:Proteasome Endopeptidase Complex; C072553:benzyloxycarbonylleucyl-leucyl-leucine aldehyde